Recently, a novel comprehensive treatment consisting of cytoreductive surgery(CRS) and perioperative chemotherapy(POC) was developed for the treatment of peritoneal metastasis(PM) with a curative intent. In the treatm...Recently, a novel comprehensive treatment consisting of cytoreductive surgery(CRS) and perioperative chemotherapy(POC) was developed for the treatment of peritoneal metastasis(PM) with a curative intent. In the treatment, the macroscopic disease is completely removed by the peritonectomy techniques in combination with POC. This article reviews the results of the comprehensive treatment for PM from gastric cancer, and verifies the effects of CRS and POC, including neoadjuvant chemotherapy(NAC) and hyperthermic intraoperative intraperitoneal chemotherapy(HIPEC). Completeness of cytoreduction, peritoneal carcinomatosis index(PCI) less than the threshold levels after NAC,absence of ascites, cytologic status, pathologic response after NAC are the independent prognostic factors. Among these prognostic factors, PCI threshold level is the most valuable independent prognostic factor. After staging laparoscopy, patients with PM from gastric cancer are recommended to treat with NAC before CRS. After NAC, indication for CRS is determined by laparoscopy. The indications of the comprehensive treatment are patients with PCI less than the threshold levels, negative cytology, and responders after NAC. Patients satisfy these factors are the candidates for the CRS and HIPEC.展开更多
I was honored to be asked to write an editorial on ＇cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy＇ （1） written by Paul H. Sugarbaker. A strategic approach usin...I was honored to be asked to write an editorial on ＇cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy＇ （1） written by Paul H. Sugarbaker. A strategic approach using peritonectomy and cytoreductive surgery to treat peritoneal cancers has gradually evolved over the past 30 years that has emanated by our impressive leader Paul H. Sugarbaker. He has brought many surgeons together from all over the world for these procedures. His skill made so many of us enthused by peritonectomy procedures and cytoreductive surgery with long operation time, a major postoperative morbidity and high mortality risk. However, we are all persisted with these procedures because of sometimes moribund patients with peritoneal cancers may cure with peritonectomy procedures and cytoreductive surgery.展开更多
文摘Recently, a novel comprehensive treatment consisting of cytoreductive surgery(CRS) and perioperative chemotherapy(POC) was developed for the treatment of peritoneal metastasis(PM) with a curative intent. In the treatment, the macroscopic disease is completely removed by the peritonectomy techniques in combination with POC. This article reviews the results of the comprehensive treatment for PM from gastric cancer, and verifies the effects of CRS and POC, including neoadjuvant chemotherapy(NAC) and hyperthermic intraoperative intraperitoneal chemotherapy(HIPEC). Completeness of cytoreduction, peritoneal carcinomatosis index(PCI) less than the threshold levels after NAC,absence of ascites, cytologic status, pathologic response after NAC are the independent prognostic factors. Among these prognostic factors, PCI threshold level is the most valuable independent prognostic factor. After staging laparoscopy, patients with PM from gastric cancer are recommended to treat with NAC before CRS. After NAC, indication for CRS is determined by laparoscopy. The indications of the comprehensive treatment are patients with PCI less than the threshold levels, negative cytology, and responders after NAC. Patients satisfy these factors are the candidates for the CRS and HIPEC.
文摘I was honored to be asked to write an editorial on ＇cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy＇ （1） written by Paul H. Sugarbaker. A strategic approach using peritonectomy and cytoreductive surgery to treat peritoneal cancers has gradually evolved over the past 30 years that has emanated by our impressive leader Paul H. Sugarbaker. He has brought many surgeons together from all over the world for these procedures. His skill made so many of us enthused by peritonectomy procedures and cytoreductive surgery with long operation time, a major postoperative morbidity and high mortality risk. However, we are all persisted with these procedures because of sometimes moribund patients with peritoneal cancers may cure with peritonectomy procedures and cytoreductive surgery.
